Among the identified candidate-drugs, Rapamycin is the prototypic mTOR (Mammalian Target of Rapamycin) inhibitor drug that can be repurposed at low dosages for the potential treatment of SARS-CoV-2 infections and autoimmune lymphoproliferative syndrome and synthetized for effective therapeutic use although it has wide range information about their activity against the SARS-CoV-2 infections [128–131]. This evidence concerns the gene MTOR and autoimmune lymphoproliferative syndrome.